Henlius Denosumab Biosimilar Trial Enters Phase III
As Firm’s Shanghai Plant Has Received EU GMP Equivalence
Henlius has administered the first dose in its international Phase III trial into its denosumab biosimilar candidate, HLX14. The firm has also revealed that its new Songjiang plant has been granted GMP equivalence with EU practices.
You may also be interested in...
Samsung Bioepis has reported positive Phase I and Phase III trial results for its SB16 proposed denosumab biosimilar to Prolia.
Amneal has struck a deal with mAbxience to gain US rights to two denosumab biosimilars referencing the Prolia and Xgeva brands that have annual US sales in excess of $4bn.
Mitsubishi Gas Chemical Company and GlycoNex have begun a Phase I trial in Japan for their SPD8 denosumab biosimilar. The partners are also “actively pursuing global development plans” for the rival to Prolia and Xgeva.